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In mammals, argonaute (AGO) proteins have been characterized for their roles in small RNA–mediated posttranscriptional and
also in transcriptional gene silencing. Here, we report a different role for AGO1 in estradiol-triggered transcriptional activation
in human cells. We show that in MCF-7 mammary gland cells, AGO1 associates with transcriptional enhancers of estrogen
receptor α (ERα) and that this association is up-regulated by treating the cells with estrogen (E2), displaying a positive
correlation with the activation of these enhancers. Moreover, we show that AGO1 interacts with ERα and that this interaction is
also increased by E2 treatment, but occurs in the absence of RNA. We show that AGO1 acts positively as a coactivator in
estradiol-triggered transcription regulation by promoting ERα binding to its enhancers. Consistently, AGO1 depletion
decreases long-range contacts between ERα enhancers and their target promoters. Our results point to a role of AGO1 in
transcriptional regulation in human cells that is independent from small RNA binding.
Introduction
Argonaute (AGO) proteins are key players in the mechanisms of
gene expression regulated by small noncoding RNAs (Meister,
2013). They have been well characterized as the effectors of
siRNA- and miRNA-mediated posttranscriptional gene silencing
(PTGS), a cytoplasmic process widely conserved along eukar-
yotes (Joshua-Tor and Hannon, 2011; Swarts et al., 2014). Briefly,
different classes of small RNAs are able to interact with AGO
proteins and, in such multimolecular complexes, to hybridize
with target mRNAs via perfect or partial RNA:RNA sequence
complementarity and to trigger mRNA endonucleolytic cleavage,
translation inhibition, or mRNA degradation, depending on the
degree of complementarity (Ipsaro and Joshua-Tor, 2015; Meister,
2013). In certain organisms, AGO proteins have also been reported
as regulators of gene expression at the transcriptional level. For
example, they are involved in siRNA-mediated transcriptional
gene silencing (TGS) in Schizosaccharomyces pombe, where they
are recruited to the pericentromeric repeats by perfect comple-
mentarity between the bound siRNAs and nascent transcripts to
further recruit histone methyl transferases that induce hetero-
chromatin formation (Holoch andMoazed, 2015). Interestingly, the
heterochromatin-forming siRNAs are generated by processing of
the transcripts generated at the same locus that is being silenced. In
a similar way, AGO proteins are responsible for small RNA–
mediated TGS in Caenorhabditis elegans (Guang et al., 2010;
Guérin et al., 2014). In Drosophila melanogaster, however, AGO
proteins were found to have a different and even opposite
role: DmAGO2 is enriched at transcriptional active genomic
loci, where it was found to interact with the transcriptional
machinery regulating transcription by either releasing RNA
polymerase II from promoter proximal pausing or by favoring
enhancer–promoter chromatin loop formation (Cernilogar
et al., 2011; Moshkovich et al., 2011). More recent evidence
reinforces the idea that DmAGO2 modulates chromatin to-
pology and gene expression in an RNAi-independent manner
(Nazer et al., 2018b, 2018a).
While several efforts have been made to elucidate a possible
role for AGO proteins in mammalian transcriptional regulation,
the matter is far from being understood, mainly because the first
reports addressing this issue used exogenous siRNAs that, when
targeted to promoter regions, resulted in H3K9me2-dependent
TGS (Han et al., 2007; Janowski et al., 2006; Morris et al., 2004).
In addition to this, exogenous siRNAs targeted to promoters and
regulatory regions have been shown to trigger transcriptional
activation (Janowski et al., 2007; Li et al., 2016) and to affect
alternative splicing decisions when targeted to introns through
a TGS-like mechanism (Alló et al., 2009). However, despite
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intense research, so far there is no evidence for endogenous
siRNAs or miRNAs driving a TGSmechanism in mammalian cells.
In humans, four AGO proteins (AGO1–4) are expressed. From
these, only AGO2 has the endonuclease activity required for
cleavage of the target mRNA (Meister, 2013). Being partially
redundant, they are all ubiquitously expressed, as it was shown
that they have binding preferences within miRNA sub-
populations (Burroughs et al., 2011). Although it was clearly
shown that AGO proteins can be found in the nuclei of human
cells (Ahlenstiel et al., 2012; Ameyar-Zazoua et al., 2012; Gagnon
et al., 2014a), compared with their well-established cytoplasmic
roles, much less is known about putative nuclear functions for
AGO proteins in mammals. As a way of addressing this question,
we previously analyzed the genome-wide distribution of AGO1 in
human mammary gland tumor cells (MCF-7 cell line) and found
that AGO1 preferentially binds transcriptional enhancers (Alló
et al., 2014). The fact that AGO1 binding prevails in active en-
hancers, as revealed by the type and level of histone marks as-
sociated with them, raises the question of whether AGO1 is
acting on transcription activation rather than in silencing. In an
independent report, others have shown that human AGO1 as-
sociates with active promoters in human prostate tumor PC3
cells, interacting with the transcriptional machinery and acting
in a positive way on transcription, whereas AGO2 showed no
genomic enrichment at all in the same cell line (Huang et al.,
2013). In contrast, it was also shown that AGO2 interacts with
estrogen receptor β (ERβ) in human BC cells and that it is in-
volved in ERβ-mediated regulation of transcription (Tarallo
et al., 2017). More recently, human AGO1 was also shown to
strongly associate with active transcriptional enhancers and
nascent RNA generated at these sites, and its depletion led to
changes in chromatin topology in HepG2 cells (Shuaib et al.,
2019). The involvement of endogenous siRNAs in AGO1 re-
cruitment to these enhancer or promoter regions is a matter that
has not yet been resolved. These intriguing observations en-
couraged us to investigate the role of AGO1 in enhancer activa-
tion and in transcription regulation in MCF-7 cells.
Many transcriptional regulatory regions or enhancers are
known to be located tens to hundreds of kilobases away from the
promoter of the regulated genes (Vernimmen and Bickmore,
2015). Understanding the mechanisms by which they function
and exert their influence over long stretches of genomic DNA is
of paramount importance. ERα enhancers are a widely used
model of signal-induced transcriptional activation. Upon estra-
diol (E2) treatment, rapid and transient transcriptional activa-
tion occurs in thousands of genes across the genome (Hah et al.,
2011). Transcriptional activation is driven by a set of primed
enhancers that become active upon ERα binding, in turn de-
pendent on hormone binding, showing increased enhancer RNA
(eRNA) levels and increased long-range interaction with their
target genes (Hah et al., 2013; Hurtado et al., 2011; Li et al., 2013;
Magnani and Lupien, 2014; Tan et al., 2011).
The evidence reported here further supports a nuclear
function for AGO1 as a transcriptional coactivator. We show that
in MCF-7 cells, AGO1 has a conspicuous nuclear localization and
almost exclusively binds to estrogen-responsive enhancers ge-
nomewide and that this binding is enhanced by treatment of the
cells with E2. Moreover, we demonstrate that AGO1 physically
interacts with ERα and that this interaction is promoted by E2
but is insensitive to RNase treatment. Upon AGO1 knockdown,
transcriptional activation of example genes controlled by E2 via
their cognate ERα enhancers is largely impaired due to the fact
that ERα recruitment to their enhancers and production of
eRNAs are reduced. We also show that AGO1 depletion de-
creases long-range contacts between ERα enhancers and their
target promoters. Furthermore, we show here that AGO1
binding to small RNAs is not needed for its role as a positive
transcriptional activator.
Results and discussion
AGO1 locates at ERα binding sites
To assess the role of AGO1 in the activity of the regulatory re-
gions to which it binds, we first decided to investigate whether
AGO1 is enriched within specific sets of transcriptional regula-
tory regions inMCF-7 cells. To focus on bona fide AGO1 sites, we
performed a new analysis of our published AGO1 chromatin
immunoprecipitation (ChIP) sequencing (ChIP-seq) data (Alló
et al., 2014) of MCF-7 cells with more stringent thresholds (see
Materials and methods). In these conditions, we detected 2,871
AGO1 binding sites. As a first exploratory approach, we per-
formed a de novo motif analysis at these AGO1-enriched regions
(Fig. 1 A). Binding motifs for numerous transcription factors
(TFs) were found to be enriched at these sites, being that the ERα
motif is the one recovered with the lowest P value (1e−134),
which was 75 orders of magnitude smaller than the second-best
match (MYBL2-like; P = 1e−59). In a subsequent analysis, the
enrichment of known binding motifs for TFs expressed in MCF-
7 cells was assessed. Consistent with the de novo analysis, this
also revealed that AGO1 regions are enriched in the ERα binding
motif: the P value with which this motif is recovered (1e−149) is
again strikingly lower than the second-best match (ESRRB; P =
1e−11) included in this analysis (Fig. S1 A). Among the other
motifs recovered, it is worth noting those for FOXA1, a pioneer
TF known to be involved in ERα enhancer priming (Magnani
and Lupien, 2014), and for AP2 TFs, also known to be involved in
ERα-mediated transcriptional activation by assisting ERα indi-
rect binding to some of the enhancers (Tan et al., 2011).
To further study the nature of AGO1-enriched regions, we
used available ChIP-seq data of several TFs obtained fromMCF-7
cells (Table S1). MCF-7 datasets include ERα ChIP-seq upon es-
tradiol treatment (+E2), FOXA1 ChIP-seq, and progesterone re-
ceptor (PR) ChIP-seq upon progestogen treatment. Both ERα and
PR belong to the family of nuclear receptors, and their binding
sites across the genome are known to partially overlap. We
found that AGO1-enriched regions are also significantly en-
riched in these TFs in MCF-7 cells (Fig. S1 B), being that ERα is
the one with the highest region overlap fold of enrichment.
Since the motif analysis revealed clear enrichment of the ERα
binding motif at AGO1 binding sites, we decided to test whether
the observed TF enrichment at AGO1-binding regions depended
on ERα cobinding. We divided the peaks of the different TFs
included in the previous analysis into bins, depending on
whether they occupied ERα binding regions (ERα+) or not
Gómez Acuña et al. Journal of Cell Biology 2 of 14
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Figure 1. AGO1 locates at ERα binding sites, and its binding is enhanced by E2. (A) De novo DNA motif analysis at AGO1-associated genomic regions.
(B) Enrichment of TF binding at AGO1-associated regions in serum-maintained MCF-7 cells, divided according to whether they are also bound by ERα (left
panel) or not (right panel). ChIP-seq peak overlaps are shown for AGO1(1), PR (2), FOXA1 (2), TEAD4 (1), CEBPB (1), and JUND (1), where the number of
replicates is shown between parentheses. (C) TF overlap with ERα-bound regions (in E2-treated cells), expressed as fold enrichment over randomized regions.
(D) Heat maps of ChIP-seq signal centered (±1 kb) on ERα binding site midpoints for ERα (+E2), AGO1 (−E2), and AGO1 (+E2) regions. Regions are ordered from
high to low ERα signal. (E) AGO1 reads per million mapped reads (RPM) around (±1 kb). AGO1 binding sites are defined by pooling AGO1 peaks from both
treatments (−E2 and +E2). (F) UCSC genome browser screenshots showing four loci comprising ERα enhancers and neighboring genes that are up-regulated
upon E2 treatment. Tracks correspond to RefSeq genes, AGO1 ChIP-seq, ERα (+E2) ChIP-seq, and GRO-seq plus and minus strands −E2 and +E2, all from MCF-
7 cells.
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(ERα−). Strikingly, only the TF binding sites that occupied ERα+
regions were enriched at AGO1 binding sites (Fig. 1 B). Those TF-
enriched regions that did not coincide with ERα had no overlap
with AGO1. We conclude then that while AGO1-enriched regions
may overlap with several TF binding regions, this is dependent
on their capacity to be associated with the ERα.
AGO1 binding to ERα target sites increases upon estradiol (E2)
treatment without changes in its subcellular localization
It is well established that ERα binds primed transcriptional en-
hancers in an E2-dependent manner (Hah et al., 2011; Hurtado
et al., 2011; Magnani and Lupien, 2014). Upon hormone treat-
ment, ERα translocates from the cytoplasm to the nucleus,
where it dimerizes and binds the transcriptional regulatory re-
gions already bound by pioneer and other TFs (Renoir, 2012).
Due to the observation that AGO1 is enriched in ERα binding
sites whenMCF-7 cells are cultured with normal serum (Fig. 1, A
and B; and Fig. S1, A and B), we decided to perform new
AGO1 ChIP-seq experiments in MCF-7 cells starved (−E2) or
treated with E2 (+E2), following the protocol depicted in Fig. S1
C. The AGO1 ChIP signal was analyzed relative to input, and this
was contrasted with known hyper-ChIPable hotspots to discard
artifactual enrichment (Teytelman et al., 2013). More than 90%
of AGO1 ChIP-seq peaks were found at ERα binding sites in ei-
ther condition (Fig. S1 D). When normalized read densities were
considered over identified peaks, samples clustered well on the
basis of replicates in contrast to E2 treatment (Fig. S1 E). AGO1
enrichment on ERα binding sites upon E2 treatment was clearly
higher than any other TF analyzed (Fig. 1 C). Although AGO1 was
also detected bound to chromatin on ERα sites in untreated cells,
AGO1 read density clearly increased in E2-treated MCF-7 cells
(Fig. 1 D). An additional analysis shows that most AGO1 binding
sites gained binding affinity in E2-treated cells (Fig. S1 F). When
total AGO1 peaks found in both conditions were analyzed, the
average AGO1 ChIP signal was also higher in E2-treated cells
than in untreated cells (Fig. 1 E). We concluded then that AGO1
binding to ERα target sites increases with E2 in MCF-7 cells.
Fig. 1 F shows four examples of genome browser snapshots
for the TFF1, GREB1, NRIP1, and FOXC1 loci, illustrating the strong
correlation between AGO1 and ERα binding to chromatin.
AGO1 E2-dependent enrichment on the highlighted regions was
confirmed by ChIP–quantitative PCR (qPCR), where ERα levels
were also assessed (Fig. S1, G and H). Additionally, an increase in
AGO1 in chromatin binding cannot be explained by an increase
in AGO1 total levels, as analyzed by Western blot (Fig. S2 A).
We next sought to determine if AGO1 binding to ERα target
sites follows changes in its subcellular localization. While the
amount of ERα observed in nuclear extracts by Western blot
clearly increased in detriment to the amount in the cytoplasmic
extracts when cells were treated with E2, AGO1 distribution
between cytoplasmic and nuclear extracts remained unchanged
(Fig. S2 B). This was also corroborated by AGO1 immunofluo-
rescent staining in fixed MCF-7 cells followed by confocal mi-
croscopy (Fig. S2, C and D). AGO1 is found in both the nucleus
and the cytoplasm, and its distribution between these com-
partments is similar in hormone-depleted and E2-treated cells.
We conclude that AGO1 displays a conspicuous nuclear
localization and that the increase in AGO1 binding to ERα
binding sites upon hormonal treatment is not due to an up-
regulation of its translocation to the nucleus.
AGO1 knockdown impairs E2-dependent ERα binding to
chromatin
A large proportion of AGO1 peaks of E2-treated cells overlaps
with ERα, but only a small proportion of ERα peaks overlaps
with AGO1. For further analysis, we divided ERα peaks accord-
ing to whether they overlap with AGO1 (ERα+/AGO1+) or not
(ERα+/AGO1−). In light of the mechanistic evidence supporting
nuclear roles of AGO2 in D. melanogaster (Cernilogar et al., 2011;
Guang et al., 2010; Moshkovich et al., 2011; Taliaferro et al.,
2013), we decided to further investigate whether AGO1 binding
to a certain fraction of ERα sites correlates with other features,
such as those included in the so-called CTCF chromatin states
(Taberlay et al., 2014). Fig. S3 A shows that, although enrichment
is very low and is similar for both ER subsets in CTCF-only
chromatin, both ERα+/AGO1+ and ERα+/AGO1− regions are
more enriched in CTCF+Enhancer− and CTCF+Promoter− chro-
matin states, with higher enrichment for ERα+/AGO1+. We then
analyzed the E2-dependent ERα normalized read counts in both
groups (Fig. 2 A). ERα normalized read counts were clearly
higher on ERα+/AGO1+ (1,935 regions) compared with ERα+/
AGO1− (6,796 regions). ERα normalized read densities on these
two groups of regions are also shown (Fig. S3 B).
To test whether ERα binding to chromatin upon E2 treatment
depends on AGO1 cobinding, we transiently knocked down
AGO1 by transfecting MCF-7 cells with specific siRNAs. Knock-
down efficiency was tested both by total protein Western blot
(Fig. 2 B) and by AGO1 ChIP-qPCR enrichment analysis on the
ERα enhancers depicted in Fig. 1 F (Fig. S3 C). It is worth noting
that depletion of AGO1 did not affect ERα total levels (Fig. 2 B).
AGO1 knockdown decreased E2-dependent binding of ERα to the
ERα+/AGO1+ sites depicted in Fig. 1 F (Fig. 2 C), which indicates
that AGO1 is involved in the first steps of ERα enhancer acti-
vation after hormone treatment. It is worth noting that the re-
duction of ERα levels upon E2 and AGO1 knockdown was not
total (i.e., levels were not reduced to the basal levels without E2).
This could be explained by the fact that AGO1 knockdown was
not total (Fig. 2 B). Alternatively, we cannot exclude that other
AGO proteins are also involved in ERα enhancer function. Fur-
ther analysis revealed that AGO1 knockdown also affects ERα
E2-dependent recruitment to ERα+/AGO1− regions (Fig. 2 D).
Considering then that a small subset of ERα peaks is cobound
with AGO1 but that all of the ERα peaks analyzed here (both
AGO1+ and AGO1−) show decreased binding levels upon AGO1
knockdown, we conclude that the latter can be explained by a
low AGO1 ChIP efficiency. AGO1 could be recruited at a lower
intensity to far more ERα regions upon E2 treatment than the
ones detected here.
AGO1 interacts with ERα in an E2-dependent manner
ERα and AGO1 display similar behaviors in their E2-dependent
binding to chromatin (Fig. 1 D and Fig. 2, C and D). To test
whether AGO1 interacts with ERα directly or within the same
protein complex, we immunoprecipitated endogenous AGO1
Gómez Acuña et al. Journal of Cell Biology 4 of 14
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Figure 2. ERα binding to chromatin depends on AGO1. (A) ERα (+E2) ChIP-seq normalized read counts over ERα+/AGO1+ and ERα+/AGO1− regions. (B–
D)MCF-7 cells were transfected with an siControl or siAGO1. 24 h later, they were hormone starved, and 72 h later, they were treated with E2 or vehicle for 1 h.
(B) AGO1 knockdown efficiency was tested by Western blot (WB) from whole-cell extracts (WCE). (C) E2-dependent ERα recruitment to ERα+/AGO1+ regions
was analyzed by ChIP-qPCR. (D) E2-dependent ERα recruitment to ERα+/AGO1− regions was analyzed by ChIP-qPCR. Values in C and D represent mean ± SE
with n = 3 (i.e., three independent experiments). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ANOVA and Tukey post-hoc test. ns, not significant;
IP, immunoprecipitation.
Gómez Acuña et al. Journal of Cell Biology 5 of 14
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from MCF-7 whole-cell extracts and analyzed the presence of
endogenous ERα in the immunoprecipitate (coimmunopreci-
pitation assay). ERα immunoprecipitates when the extracts are
incubated with an anti-AGO1 antibody and not with a control
antibody (Fig. 3 A). Moreover, the efficiency of bringing down
ERαwith the anti-AGO1 antibody is higher when treating MCF-
7 cells with E2 compared with hormone-starved cells (Fig. 3 A;
compare lanes 1, 3, 5, and 7). As coimmunoprecipitation assays
were performed with whole-cell extracts as starting material, it
is unlikely that the differential coimmunoprecipitation ob-
served with E2 was due to the different compartmentalization
observed in Fig. S2 D. ERα is subjected to many posttransla-
tional modifications upon ligand binding (Le Romancer et al.,
2011), allowing us to speculate that this result might be due to
AGO1 interacting directly or indirectly to ERα harboring spe-
cific posttranslational modifications.
AGO1 association with chromatin correlates with
eRNA expression
We next decided to investigate whether AGO1 is associated with
enhancer activation. In the previous report (Alló et al., 2014), we
showed that AGO1 is preferentially enriched at active tran-
scriptional enhancers, as revealed by the nature and level of the
histone marks typically associated with active enhancers. Ac-
cordingly, when comparing ERα binding sites that are also
bound by AGO1 (ERα+/AGO1+; 1,935 regions) with those that are
not (ERα+/AGO1−; 6,796 regions), we observed that +E2/−E2 fold
change in eRNA levels was higher in ERα+/AGO1+ than in ERα+/
AGO1− (Fig. 4 A). Considering that enhancer transcription into
eRNAs is the best marker for enhancer activation (Hah et al.,
2013; Li et al., 2013), we conclude that AGO1 enrichment on ERα
enhancer positively correlates with enhancer activation levels.
AGO1 is necessary for the transcriptional activation by E2 of
genes controlled by ERα enhancers
The above-demonstrated interaction between AGO1, ERα, and
ERα enhancers, although specific, could be a circumstantial
event without further relevant biological implications. The fact
that these interactions do not require the participation of small
RNAs, or in fact any kind of RNA (Fig. 3 A), suggests that if a
function exists, this must be novel and unrelated to both PTGS
and TGS. We then sought to determine if AGO1 is necessary for
the transcriptional activation of the ERα enhancers. We based
this analysis on the four previously chosen loci (Fig. 1 F) in
which GRO-seq tracks (Li et al., 2013) showed eRNA up-
regulation at the ERα enhancers upon E2 treatment. The
tracks also showed the E2-dependent transcriptional activation
of their neighboring genes (TFF1, GREB1, NRIP1, and FOXC1),
which we will consider as targets (Li et al., 2013). We first an-
alyzed the eRNA levels generated from the ERα enhancers in
cells subjected to AGO1 knockdown and E2 treatment for 1 h by
reverse transcriptase qPCR (RT-qPCR). AGO1 knockdown effi-
ciency was assessed here by RT-qPCR (Fig. 4 B). AGO1 knock-
down abolishes the up-regulation of enhancer transcription
(Fig. 4 C) consistently, with the idea that ERα enhancer activa-
tion is dependent on AGO1. Accordingly, transcriptional ac-
tivation of the target genes is greatly inhibited by AGO1
depletion, both at the pre-mRNA (Fig. 4 D) and the mature
mRNA (Fig. S3 D) levels. No changes in pre-mRNA levels were
observed in the case of non–E2-regulated genes (Fig. 4 E),
pointing to a specific role of AGO1 in ERα-regulated gene ex-
pression in MCF-7 cells, although genome-wide expression
studies are lacking at this point. Similar effects are observed
in independent experiments in which a different siRNA to AGO1
mRNA was transfected (Fig. S3 E), arguing against possible off-
target artifacts.
As a first step to understand the role of AGO1 in transcription
of genes regulated by ERα enhancers, we performed chromo-
some conformation capture (3C) at three different loci (corre-
sponding to the E2-regulated genes NRIP1, TFF1, and GREB1) and
found that the long-range interaction observed between the ERα
enhancers and the promoter regions of their target genes were
reduced upon AGO1 knockdown (Fig. 4 F). No significant re-
duction was observed in the interactions between the FOS1 gene
promoter and its closest ERα binding site that does not bind
AGO1 and between the FOS1 gene promoter and a negative
control region (Fig. 4 G). Finally, as an additional negative
control, no changes in the interaction between the non–E2-
Figure 3. AGO1 physically interacts with ERα in an E2-dependent and RNA-independent manner. (A) MCF-7 cells were hormone starved and treated
with vehicle or E2 for 1 h. Whole-cell extracts (WCE) were treated or not with RNase A, and then they were immunoprecipitated (IP) with control or anti-AGO1
antibody. AGO1 and ERα presence in inputs and immunoprecipitates was analyzed by Western blot (WB). (B) Representative agarose gel showing RNase
treatment efficiency.
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Figure 4. AGO1 participates in the transcriptional activation of E2-responsive genes controlled by ERα enhancers by promoting three steps of ERα
enhancer activation. (A) GRO-seq read count fold change between −E2 and +E2 treatments over ERα+/AGO1+ and ERα+/AGO1− regions. (B–H) MCF-7 cells
Gómez Acuña et al. Journal of Cell Biology 7 of 14
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regulated gene DUSP1 and its enhancer (not bound by ERα) were
observed (Fig. 4 H).
AGO1 functional role at ERα transcriptional enhancers does
not depend on small RNA binding
AGO proteins bind small RNAs and are widely known to interact
with mRNAs through RNA:RNA complementarity. The above-
reported AGO1 and ERα interaction, however, was not affected
upon treatment of MCF-7 whole-cell extracts with RNase A be-
fore and during incubations with the specific and control anti-
bodies (Fig. 3 A, lanes 3, 4, 7, and 8). To further explore a
putative role of small RNAs in AGO1 function at ERα tran-
scriptional enhancers, we decided to use an AGO1 mutant that
fails to bind small RNAs (Faehnle et al., 2013; Rüdel et al., 2011;
Fig. 5 A). This AGO1 mutant bears a phospho-mimetic point
mutation at the MID domain (Y527E) that impairs binding to the
59 overhang of the small RNAs (Faehnle et al., 2013; Rüdel et al.,
2011). AGO1was knocked down inMCF-7 cells using siRNAs, and
rescue of AGO1 loss of function was attempted by expression of
adenoviral vectors encoding GFP, AGO1 WT, or AGO1 Y527E. As
shown in Fig. 5 B, AGO1 knockdown efficiency is high, and
rescue protein levels with the exogenous constructs are similar
to the endogenous (siRNA control [siControl] + GFP) ones. As
observed in Fig. 2 C, expression of the E2-regulated genes TFF1
and GREB1, measured at the pre-mRNA level, is reduced upon
AGO1 knockdown, and expression levels are reestablished when
rescuing AGO1 expression with either the WT or the Y527E
mutant constructs (Fig. 5 C). eRNA levels of the FOS1 E2-
regulated enhancer (corresponding to an ERα+/AGO1− region)
are not changed by knocking down AGO1 or rescuing its ex-
pression with either construct, although the same trend is ob-
served (Fig. 5 D). In line with reports highlighting small
RNA–independent nuclear roles of AGO proteins in D. mela-
nogaster (Zaytseva et al., 2020 Preprint), the evidence reported
here points us to a positive role of AGO1 in E2-regulated gene
expression that does not depend on small RNA binding and small
RNA-–RNA interactions.
Many proteins are found, named, and characterized for a
particular function to later discover that they participate in cell
processes that are completely different from those of the original
findings. This seems to be the case with human AGO1, a protein
primarily characterized as a key factor in cytoplasmic PTGS and
with some evidence for roles in nuclear TGS.We uncovered here
a role for AGO1 in estradiol-triggered transcriptional activation
in human cells. Following our previous findings that AGO1 binds
transcriptional regulatory regions preferentially when active,
we show here that in the tumor-derived MCF-7 mammary gland
cells, AGO1 associates with ERα transcriptional enhancers and
that this association is up-regulated by treating the cells with E2,
which displays a positive correlation with the activation level of
these enhancers. Moreover, we show that AGO1 physically in-
teracts with ERα either directly or in the same protein complex,
and again, this interaction is increased by E2 treatment. Fur-
thermore, the interaction occurred in the absence of RNA.While
ERα translocates to the nucleus upon E2 treatment, we dem-
onstrated that the nucleo/cytoplasmic distribution of AGO1 was
quantitatively similar in both untreated and E2-treated cells.
This evidence suggests that the ERα/AGO1 interaction occurs
when both proteins are bound to chromatin. Most importantly,
our analysis of a few, well-characterized, E2-regulated loci
supports the notion that AGO1 acts positively in estradiol-
triggered transcriptional activation: AGO1 knockdown reduced
(i) ERα binding to the enhancers, (ii) the transcriptional acti-
vation level of the target genes, and (iii) the long-range inter-
action between enhancers and their target gene promoter. In
addition, we show that the inhibition of E2-dependent tran-
scriptional activation of the studied target genes by AGO1
knockdown can be equally rescued by both WT AGO1 and the
Y527E mutant, unable to bind to the 59 overhang of small RNAs.
This provides further evidence that RNA binding is dispensable
for the new role of AGO1 reported here.
Based on the above evidence and the lack of a DNA-binding
domain, we wish to propose that AGO1 is a transcriptional co-
activator, since it fits the textbook definition of “a protein that
does not itself bind DNA but assembles on other DNA-bound
gene regulatory proteins to activate transcription of a gene”
(Alberts et al., 2015). More specifically, because of its interaction
with a nuclear receptor (ERα) and results in Fig. 4, AGO1 per-
fectly fits the definition of a nuclear receptor coregulator (i.e., a
cellular factor recruited by nuclear receptors that complements
their function as mediators of the cellular response to endocrine
signals; McKenna and O’Malley, 2002). Coregulators include
coactivators and corepressors. One may wonder whether AGO1
also acts as a corepressor of certain genes. Indeed, steroid hor-
mone receptors are able to repress transcription by inducing
chromatin compaction around the transcription start sites of
target genes in a mechanism that involves HP1γ-LSD1 repressor
complex recruitment to the promoter regions (Nacht et al.,
2016). Repression acts, however, at the level of gene pro-
moters and not at distal enhancers, which seems unlikely for
AGO1 in light of the evidence reported here.
Due to concerns about the specificity of AGO1 antibodies, we
previously validated the one used here (4B8) exhaustedly
(Sigma-Aldrich; Alló et al., 2014). Additionally, we can argue
were transfected with an siControl or siAGO1. 24 h later, they were hormone starved, and 72 h later, they were treated with E2 or vehicle for 1 h. (B) Total RNA
was extracted, and AGO1 knockdown was assessed by RT-qPCR. (C) Nuclear RNA was extracted, and the indicated eRNA levels were analyzed by RT-qPCR.
(D) Total RNA was extracted, and the indicated pre-mRNA levels corresponding to E2-regulated genes were analyzed by RT-qPCR. (E) Total RNA was ex-
tracted, and the indicated pre-mRNA levels corresponding to non–E2-regulated genes were analyzed by RT-qPCR. (F) Frequency of chromatin loops formation
between the indicated restriction fragments was analyzed by 3C. The anchor region, with which all of the interactions were tested, comprises an ERα+/AGO1+
region. AGO1 ChIP-seq and ERα ChIP-seq tracks are shown along the position of the proximal E2-regulated genes. (G) Same as F, but here the anchor region
comprises an ERα+/AGO1− region. (H) Same as G, but here the anchor region comprises a non–E2-regulated enhancer region. Values in B–E represent mean ±
SE from three independent experiments (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ANOVA and Tukey post-hoc test). Values in F–H represent mean ± SE
from three independent experiments (*, P < 0.05; **, P < 0.01; two-tailed Student’s t test).
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against a putative cross reactivity with another protein of the
AGO1 4B8 antibody used in our ChIP and coimmunoprecipita-
tion assays. First, two different siRNAs targeting AGO1 mRNA
are capable of reducing AGO1 levels detected by Western blot-
ting using the same antibody used in our ChIP experiments.
Second, AGO1 ChIP-qPCR enrichment levels are also reduced
when specifically knocking down AGO1.
The role of AGO1 in transcriptional activation described here
in human cells resembles the one found in D. melanogaster,
whereby DmAGO2 binds transcriptionally active genomic re-
gions either by interacting with the transcriptional machinery
(Cernilogar et al., 2011; Nazer et al., 2018b) or by acting in
transcriptional regulation by modulating chromatin topology
(Moshkovich et al., 2011; Nazer et al., 2018a). Our findings do not
contradict previous evidence showing that exogenous siRNAs
targeted to genomic regions (promoters and introns) induce
local heterochromatin formation (Alló et al., 2009; Han et al.,
2007; Janowski et al., 2006; Morris et al., 2004). While the
generation of endogenous siRNAs inmammalian cells is a matter
of controversy (Gantier andWilliams, 2007; Svoboda, 2014; Tam
et al., 2008), it is conceivable that when siRNAs are provided
exogenously, AGO1 and other components of the nuclear RNAi
machinery are capable of performing TGS. In this context, our
results are consistent with the observation that transfection of
siRNAs targeted to promoter regions can induce transcriptional
activation (Janowski et al., 2007; Li et al., 2016), probably helped
by AGO proteins.
We found here a strong association between AGO1 and ERα
enhancers in MCF-7 cells. We wonder, however, whether AGO1
activity on transcriptional enhancers is restricted to ERα en-
hancers alone or whether it can also be extended to hormone-
responsive enhancers in general or to other signal-dependent or
developmental enhancers. AGO1 was also reported to bind ac-
tively transcribed loci genome wide in HepG2 and K562 cells,
contributing to global 3D genome architecture (Huang et al.,
2013; Shuaib et al., 2019; Xiao et al., 2019). It was also reported
that human AGO2 interacts with ERβ (Tarallo et al., 2017), which
shares high sequence identity with ERα. All together, these and
Figure 5. AGO1 functional role at ERα transcriptional enhancers does not depend on small RNA binding. (A) Schematic representation of AGO1 protein
domains showing the position of the point mutation in the MID domain that impairs small RNA binding. (B–D)MCF-7 cells were transfected with the indicated
siRNAs, and AGO1 expression was rescued by the indicated constructs before hormone starvation and E2 treatment. (B) AGO1 knockdown and rescue levels
were assessed by Western blot. RPB1 corresponds to the housekeeping control. (C) The levels of the indicated pre-mRNA corresponding to E2-regulated genes
were assessed by RT-qPCR. (D) The levels of the indicated eRNA corresponding to an E2-regulated eRNA were assessed by RT-qPCR. Values in C and D
represent mean ± SE from three independent experiments (*, P < 0.05; two-tailed Student’s t test). ns, not significant; WCE, whole-cell extracts.
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our results reveal that AGO proteins play crucial roles in
hormone-induced transcriptional activation. In a broader sce-
nario, our findings fit with the fact that in a comprehensive
study, many RNA-binding proteins were found to bind chro-
matin and to regulate transcription (Xiao et al., 2019).
Materials and methods
Cell culture and treatment
MCF-7 breast cancer cells were routinely grown in DMEM/nu-
trient mixture F-12 supplemented with 10% FBS and 100 µg/ml
of Primocin (InvivoGen), which is active against bacteria, my-
coplasma, and fungi. Cells were routinely checked for myco-
plasma infection. For the experiments, cells were plated in the
same media at a density of 2 × 105 cells in 12-well plates, and for
24 h, they were hormone starved by washing them thoroughly
with PBS, adding DMEM/F-12 media without phenol red, and
supplementing with 2% dextran-coated, charcoal-treated FBS.
72 h later, cells were treated with β-estradiol (E2, E8875; Sigma-
Aldrich) or vehicle for the indicated time and harvested for
downstream applications.
HEK293 cells were routinely grown in DMEM supplemented
with 10% FBS, 100 U/ml of penicillin, and 100 µg/ml of
streptomycin.
siRNA transfection
For knockdown experiments, siRNA transfections were per-
formed 24 h after cells were plated using 3 µl of Lipofectamine
2000 (Thermo Fisher Scientific) per well of 12-well plates and
siRNAs at a concentration of 25 nM. Cells were hormone starved
24 h after transfection as indicated before. 72 h later, cells were
treated with β-estradiol or vehicle for the indicated time and
harvested for downstream applications. Thermo Fisher Scien-
tific Block-iT siRNAs with the following sequences were used:
siControl, 59-CUUACGCUGAGUACUUCGAdTdT-39; siAGO1, 59-G
AGAAGAGGUGCUCAAGAAdTdT-39; and siAGO1_2, 59-AAACC-
CAAACCUAACCAGCdTdT-39.
Plasmid transduction
For knockdown and rescue experiments, plasmids harboring
different DNA constructs were packed into lentivirus and
transduced into MCF-7 cells. For lentivirus production, HEK293
cells were used. Briefly, 4.5 × 106 HEK293 cells were seeded on a
10-cm dish 24 h before transfection. 1 h before transfection,
medium was replaced with DMEM containing 10% FCS and
25 µM chloroquine. The following transfection mix was pre-
pared, vortexed, let stand for 15 min at room temperature, and
added to the cells: 1 ml DMEM (no FCS and no antibiotics), 1.6 µg
pMD2.G (VSV-G viral envelope; Addgene plasmid 12259), 3.2 µg
pCMVdR8.74 (packaging construct; Addgene plasmid 22036), 6.5
µg of the viral transfer plasmid, and 4 µg of polyethylenimine
per microgram of DNA used. 6 h after transfection, mediumwas
replaced with 8 ml of fresh DMEM containing 10% FCS. 48 h
after transfection, 8 ml of culture medium containing the len-
tiviral particles was removed, and Polybrene at an 8-µg/ml final
concentration was added. Aliquots were prepared and used
immediately or stored at −80°C.
For knockdown and rescue experiments, 8 × 105 MCF-7 cells
were seeded in 6-cm dishes and transfected with siRNAs as
specified before. 24 h after siRNA transfection, cells were in-
fected with the lentivirus prepared before. 1 h before infection,
the medium was replaced with fresh medium containing 8 µg/
ml Polybrene. The medium was then replaced with the medium
containing the lentiviral particles at a 1:2 dilution if used fresh or
nondiluted if used from the −80°C stock. 24 h after infection,
cells were hormone starved as indicated before. 72 h later, cells
were treated with β-estradiol or vehicle for the indicated time
and harvested for downstream applications.
Plasmid constructions
The lentiviral vector driving expression of FLAG/HA-Ago1 (hu-
man) from the Syn promoter (pLV-FLAG-HA_Ago1) was gen-
erated by amplifying FLAG/HA-Ago1 from pIRESneo-FLAG/HA
Ago1 (Addgene plasmid 10822). Site-directed mutagenesis was
performed by the DpnI method, based on Stratagene’s Quick-




Approximately 1–2 × 107 MCF-7 cells were cross-linked for
10 min in 1% formaldehyde in PBS at room temperature. Cross-
linking reaction was stopped with glycine at a final concentra-
tion of 125 mM. Cells were washed twice with cold PBS and
swelled on ice for 10 min in 5 mM Pipes, pH 8, 85 mM KCl, 0.5%
Igepal CA630, and 1× protease inhibitor cocktail (Roche). Fol-
lowing centrifugation, the pellet enriched in nuclei was re-
suspended in 0.5 ml sonication buffer (50 mM Tris-HCl, pH 8.1,
1% SDS, and 10 mM EDTA, pH 8). DNA was sonicated in an ul-
trasonic bath (Bioruptor Diagenode) to an average length of
200–500 bp, and samples were centrifuged at 15,000 g. 20–40
µg of DNA was used in each immunoprecipitation, diluting
chromatin at least 10 times in 1 ml immunoprecipitation buffer
(15 mM Tris-HCl, pH 8.1, 1% Triton X-100, 1 mM EDTA, pH 8,
150 mM NaCl, and 1× protease inhibitor cocktail). Chromatin
was immunoprecipitated overnight with 40 µl of protein G
magnetic beads (Dynabeads Protein G; Thermo Fisher Scientific)
previously incubated with the antibody of interest for 1 h at 4°C.
The following antibodies were used: 5 µg of rat monoclonal anti-
AGO1 clone 4B8 and 2 µg of rabbit polyclonal anti-ERα HC-20
(Santa Cruz Biotechnology). Control immunoprecipitationswere
performed with no antibody. Beads were washed sequentially
for 5 min each in low-salt (20 mMTris-HCl, pH 8, 150 mMNaCl,
2 mM EDTA, 1% Triton X-100, and 0.1% SDS), high-salt (20 mM
Tris-HCl, pH 8, 500 mM NaCl, 2 mM EDTA, 1% Triton X-100,
and 0.1% SDS), and LiCl buffer (10mMTris, pH 8.0, 1 mMEDTA,
250 mM LiCl, 1% Igepal CA630, and 1% sodium deoxycholate) for
5 min at 4°C and then twice in 1× Tris-EDTA (TE) for 5 min at
room temperature. Beads were eluted in 1% SDS and 100 mM
NaHCO3 buffer for 1 h at room temperature, and cross-linking
was reversed overnight after addition of NaCl to a final con-
centration of 200 mM and 2 µg of proteinase K. DNA was pu-
rified with Qiaquick PCR purification columns (Qiagen) as
indicated by the manufacturer.
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For ChIP-qPCR, immunoprecipitated DNA was analyzed with
SYBR-Green real-time qPCR using the standard-curve method,
and quantity was expressed relative to input. ChIP-qPCR ex-
periments were performed in triplicate. Primer sequences are
listed in Table S2. For ChIP-seq, libraries were prepared using
NEBNext Ultra II DNA Library Prep Kit for Illumina according to
the manufacturer’s instructions. NEBNext Multiplex Oligos for
Illumina were used during library amplification. Single-ended
sequencing was performed using the NextSeq 500/550 High-
Output v2.5 (75 cycle) Kit (#20024906) on the NextSeq 550
platform at the Wellcome Trust Clinical Research Facility in
Edinburgh, UK. ChIP-seq experiments were performed in
duplicate.
Bioinformatics analysis
Read mapping and data visualization
ChIP-seq data generated here and publicly available raw datasets
(ChIP seq and GRO-seq listed in Table S1) were aligned and
processed as follows. Single-end ChIP-seq reads were mapped to
the hg18 genome using Bowtie v1.0.0 (Langmead et al., 2009).
Only sequences uniquely aligned with less than or equal to one
mismatch were retained. The resulting files (.sam) were then
converted into bam files using SAMtools (Li et al., 2009). Du-
plicated reads were removed using the SAMtools rmdup com-
mand (Li et al., 2009). For signal normalization and visualization
on the University of California, Santa Cruz (UCSC) genome
browser (Kent et al., 2002), the number of reads per kilobase per
million mapped reads was counted using the bamCoverage
command from deepTools (Ramı́rez et al., 2014), and BigWig
files were generated. For Chip-seq datasets, reads were extended
to 200 bp.
Peak calling
TF enrichment sites were detected with MACS2 version 2.1.1
(Zhang et al., 2008) using default parameters and a P value of
1e−5. A control dataset derived by sequencing input DNA sam-
ples was used to define a background model. For samples for
which duplicate samples were available, we retained the peaks
found in replicate experiments. We considered peaks to be
overlapping if they shared a minimum of one base.
Motif discovery
De novo motif discovery was performed with HOMER (Heinz
et al., 2010) using a window of 200 bp around the peak summits
and setting motifs length to 8, 10, and 12 bp. The best scoring
motif was chosen from each analysis to represent the DNA
binding domain for each of the factors profiled. The coenriched
motifs obtained for the different lengths were independently
analyzed for consistency of results and manually curated to
exclude redundant motifs. The top scoring motifs, ranked by P
value, are shown in each case. Matching in vitro or in vivo DNA
binding motifs were associated with the de novo recovered
matrix when the HOMER score was 0.7 or higher.
Heat maps, average profiles, and differential binding analysis
Heatmaps and average profiles for TF binding sitemidpointswere
generated using deepTools (Ramı́rez et al., 2014). Differential
binding analysis and related plots were performed as described
previously (Stark and Brown, 2011). ChIP-seq read counts were
TMM (trimmed mean of M values) normalized using full library
size. GRO-seq read densities were analyzed in a manner similar to
that of ChIP-Seq, and raw read counts from estradiol-treated
samples were divided by the raw read count from the control-
treated samples.
Subcellular fractionation and Western blotting
Subcellular fractionation was performed as previously described
(Gagnon et al., 2014b). A pellet of ∼5–10 × 106 MCF-7 cells was
washed in ice-cold PBS and resuspended in HLB buffer (10 mM
Tris-HCl, pH 7.5, 10 mM NaCl, 3 mMMgCl2, 0.3% Igepal CA630,
10% glycerol, and 1× protease inhibitors; Roche). 10-min incu-
bation was performed in ice. Samples were centrifuged at 4°C
and 800 g for 8 min. The pellet corresponds to intact nuclei
and the supernatant to the cytoplasmatic fraction. Equal pro-
portions of each fraction were analyzed by SDS-PAGE and
transferred to nitrocellulose membranes (BioRad). Membranes
were blocked with 5%milk and then incubated with the primary
antibody. After washing, membranes were incubated with IR-
Dye 800CW (LI-COR Biosciences) secondary antibodies. Bound
antibody was detected using the Odyssey imaging system (LI-
COR Biosciences).
Immunofluorescence
Cells were grown and treated on coverslips. They were fixed in
4% paraformaldehyde for 10 min and permeabilized in 1% Triton
X-100 in PBS for another 10 min. Cells were blocked with 3%
BSA in PBS for 30 min and further incubated with the primary
antibody in a 1/1,000 dilution in blocking buffer for 1 h. Rat
monoclonal anti-AGO1 antibody clone 4B8 was used. Cells were
then incubated with the secondary antibody diluted 1/1,000 in
3% BSA PBS for 1 h. The secondary antibody used was the anti-
goat anti-rat (Alexa Fluor 488; Abcam ab150157). Coverslips
were washed with PBS for 5 min five times. Nuclei were stained
with TOTO-3 iodide (Thermo Fisher Scientific). Images were
taken with an Olympus FV1000 inverted confocal microscope
using a 60× oil-immersion objective and FluoView Viewer
software (Olympus). Images were further analyzed using Cell-
Profiler software (Carpenter et al., 2006).
Coimmunoprecipitation assay
A pellet of ∼2 × 106 MCF-7 or HEK293 cells was lysed in 1 ml of
lysis buffer (50mMTris-HCl, pH 7.5, 150mMNaCl, 1 mMEDTA,
1% Igepal CA630, 0.5% sodium deoxycholate, 0.5 mM DTT, 1×
protease inhibitors [Roche], 5 mM β-glycerophosphate, and
5 mMpotassium fluoride) and incubated for 30min at 4°C. After
centrifugation for 20 min at 4°C, supernatants were im-
munoprecipitated overnight with 40 µl of protein G magnetic
beads previously incubated with the antibody of interest for 1 h
at 4°C. The following antibodies were used: 2 µg of rat mono-
clonal anti-AGO1 clone 4B8, 1 µg of rabbit polyclonal anti-ERα
HC-20, and 2 µg of mouse monoclonal anti-FLAG clone M5
(Sigma-Aldrich). Control immunoprecipitations were per-
formed with no antibody. Beads were washed four times with
washing buffer (50 mM Tris-HCl, pH 7.5, 125 mM NaCl, 1 mM
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EDTA, and 0.1% Igepal CA630) for 5 min at 4°C. Immunopre-
cipitate was eluted with 2× Laemmli sample buffer.
Expression analysis
RNA from MCF-7 cells grown in 12-well plates or MCF1 nuclei
purified as explained before from 6-cm plates were isolated by
using 500 µl of Tri-Reagent (MRC) following the manufacturer’s
instructions. 2 µg was reverse transcribed to cDNA with a ran-
dom deca-oligonucleotide primer mix using MMLV Reverse
transcription (Invitrogen). qPCRs were performed using SYBR
Green dye and Taq DNA polymerase (Invitrogen). The annealing
temperature was 60°C, and the elongation time at 72°C was 30 s.
Relative RNA abundances from cDNAs and no-reverse tran-
scription controls were estimated using internal standard curves
with a PCR efficiency of 100 ± 10% for each set of primers in each
experiment. Primer sequences are listed in Table S2.
3C
3C assay was performed as described before (Louwers et al.,
2009; Naumova et al., 2012). 25 × 106 MCF-7 cells were fixed
by adding 1% formaldehyde at room temperature for 10 min, and
the reactionwas stopped with 125 mM glycine. Lysis buffer (500
µl of 10 mM Tris-HCl, pH 8.0, 10 mM NaCl, 0.2% Igepal CA630,
and 1× protease inhibitors) was added, and cells were incubated
on ice 15 min. Next, cells were lysed with a Dounce homoge-
nizer, and the suspension was spun down at 5,000 rpm at 4°C.
The pellet was washed twice with 500 µl ice-cold 1× NEBuffer 2.
The pellet was then resuspended in 1× NEBuffer 2 and split into
five separate 50-µl aliquots. 362 µl of NEBuffer 2 was added to
each aliquot. SDS was added to a 0.1% final concentration, and
incubation at 65°C was performed for 10 min. Triton X-100 at a
1% final concentration was added, and nuclei were incubated at
37°C on a rotating wheel. Next, chromatin was digested over-
night with 200 U NcoI (NEBuffer 2). On the next morning, 86 µl
of 10% SDS was added to each tube, and they were incubated at
65°C for 10min. Each digested chromatin mixture was ligated by
100 U T4 DNA Ligase (Promega) in 8 ml of Ligation Mix (1%
Triton X-100, 1× Ligation Buffer, 1 mMATP, and 0.1 mg/ml BSA)
for 4 h at 16°C. The ligase step was omitted in one chromatin
aliquot from the five mentioned above as the unligated control.
The chromatin was subsequently de–cross-linked overnight at
65°C with 50 µg of proteinase A. DNA was purified twice with
phenol and then with a mixture of phenol and chloroform (at a
ratio of 1:1). DNA was precipitated, and pellets were air dried
before resuspending in 250 µl 1× TE buffer. To degrade any
carryover RNA, 1 µl RNase A was added to each tube and incu-
bated at 37°C for 15min. DNAwas further purified using phenol/
chloroform and then precipitated. The digestion and ligation
efficiencies were checked and normalized before DNA analysis
by SYBR-Green qPCR. Primer sequences are listed in Table S2.
Online supplemental material
Fig. S1 further supports our findings showing that AGO1 local-
izes at ERα binding sites in MCF-7 cells and that that AGO1
binding levels to chromatin increase with E2 treatment. It also
shows ChIP-qPCR validation of AGO1 ChIP-seq findings. Fig. S2
shows both by subcellular fractionation followed by Western
blot and by immunofluorescence that AGO1 nuclear relative to
cytoplasmatic localization remains unchanged upon E2 treat-
ment. Fig. S3 shows the enrichment levels of different chro-
matin states on ERα binding sites divided into AGO1+ and AGO1−.
Fig. S3 further shows that ERα binding density is higher in AGO1
cobound regions. Additionally, it shows by ChIP-qPCR that AGO1
knockdown reduces its recruitment levels to chromatin and that
AGO1 knockdown performed with two different siRNAs reduces
the E2-dependent increase inmRNA levels (shown by RT-qPCR).
Table S1 lists the citations corresponding to the published data
used for the bioinformatic analysis. Table S2 lists the primer
sequences used in this paper.
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Figure S1. Relative to Fig. 1: AGO1 locates at ERα binding sites, and its binding is enhanced by E2. (A) Analysis of known DNA binding motifs of TFs
expressed in MCF-7 cells at AGO1-associated genomic regions in serum-maintained cells. (B) Enrichment of TF binding at AGO1-associated regions in serum-
maintained MCF7 cells. (C) Schematic representation of the hormone treatment experiments time line. (D) Table showing the overlap between the number of
genomic sites (peaks) bound by ERα and by AGO1, considering each replicate separately and the common peaks. (E) Correlation heat map between AGO1 ChIP-
seq samples and replicates based on read counts data on peak sets. (F) MA plot (gene expression ratios [Yang et al., 2002] depicting fold changes in AGO1
binding affinity between untreated and treated samples. (G and H) MCF-7 cells were hormone starved and then treated with vehicle or E2 for 1 h. (G) ERα
binding to the enhancers was assessed by ChIP-qPCR. Data are represented as mean ± SD (n = 3). IP, immunoprecipitation. (H) AGO1 binding to the enhancers
was assessed by ChIP-qPCR. Data are represented as mean ± SD (n = 3; *, P < 0.05; **, P < 0.01; two-tailed Student’s t test).
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Figure S2. AGO1 locates at ERα binding sites, and its binding is enhanced by E2without changes in its subcellular localization. (A–D)MCF-7 cells were
hormone starved and then treated with vehicle or E2 for 1 h. (A) AGO1 levels in starved (−E2) and E2-treated (+E2) cells were tested byWestern blot (WB) from
whole-cell extracts (WCE; lanes 1–4). AGO1 levels were also assessed under these same conditions but transfected with a specific siRNA against AGO1 (lanes
5–8). (B) AGO1 and levels were assessed by Western blot in nuclear (NE) and cytoplasmic extracts (CE) from starved (−E2) and E2-treated MCF-7 cells.
(C) AGO1 subcellular localization was assessed by immunofluorescence followed by confocal microscopy. The box plot corresponds to nucleus/cytoplasm
integrated intensity ratios (n = 100 cells; two-tailed Student’s t test). (D) Panels show representative images from C. Scale bars represent 10 µm.
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Figure S3. Relative to Figs. 2 and 4. ERα binding intensity positively correlates with AGO1 binding, and AGO1 participates in the transcriptional
activation of E2-responsive genes controlled by ERα enhancers. (A) Enrichment of the indicated chromatin states, obtained from E2-treated MCF-7 cells,
over ERα binding sites divided into ERα+/AGO1+ and ERα+/AGO1−. (B). Heat maps of ChIP-seq signal centered (±3 kb) on ERα binding site midpoints for ERα
(+E2), AGO1 (−E2), and AGO1 (+E2). ERα regions were divided according to whether they overlap with AGO1 (ERα+/AGO1+) or not (ERα+/AGO1−), and within
each group, they were ordered from high to low ERα signal. (C–E) MCF-7 cells were transfected with an siControl or siAGO1. 24 h later, they were hormone
starved, and 72 h later, they were treated with E2 or vehicle for the indicated time. (C) E2-dependent AGO1 recruitment to the enhancers upon AGO1
knockdown was controlled by ChIP-qPCR. Data are represented as mean ± SD (n = 3; *, P < 0.05; **, P < 0.01; two-tailed Student’s t test). (D) RNA was
extracted, and the indicated mRNA levels were analyzed by RT-qPCR. (E) Same as D, but a different siRNA against AGO1 was used. Values in D and E represent
mean ± SE from three independent experiments (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ANOVA and Tukey post-hoc test). In A and B, two
different siRNAs against AGO1 were used.
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Provided online are two tables. Table S1 lists datasets used in the bioinformatic analysis, and Table S2 lists the oligonucleotides
used in this study.
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